Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - roxithromycin -

Belgia - hollanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - roxithromycine 150 mg - filmomhulde tablet - 150 mg - roxithromycine 150 mg - roxithromycin

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; magnesium stearate; purified talc; povidone; titanium dioxide; maize starch; propylene glycol; hyprolose - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: glucose; propylene glycol; colloidal anhydrous silica; hyprolose; maize starch; povidone; hypromellose; magnesium stearate; titanium dioxide; purified talc - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Ranska - ranska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teva sante - roxithromycine 100 mg - comprimé - 100 mg - pour un comprimé > roxithromycine 100 mg - antibactériens à usage systémique - classe pharmacothérapeutique : antibacteriens a usage systemique - code atc : j01fa06ce médicament est indiqué dans le traitement de certaines infections bactériennes à germes sensibles.

Ranska - ranska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teva sante - roxithromycine 150 mg - comprimé - 150 mg - pour un comprimé > roxithromycine 150 mg - antibactériens à usage systémique - classe pharmacothérapeutique : antibactériens à usage systémique - code atc : j01fa06 (j: anti-infectieux).il est utilisé pour le traitement de certaines infections bactériennes à germes sensibles (pouvant être détruits par cet antibiotique).

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

ratiopharm gmbh, ulm array - 9714 roxithromycin - potahovaná tableta - 150mg - roxithromycin